Buchumschlag

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Richard J. MacIsaac, Philippa Trevella, Elif I. Ekinci
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Journal of Diabetes
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Glucagon‐like‐peptide‐1 receptor agonists versus dipeptidyl peptidase‐4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study
von: Bochra Zareini, et al.
Veröffentlicht: (2024)

Glucagon‐like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed?
von: Dario Giugliano, et al.
Veröffentlicht: (2025)

Glucagon‐like peptide ‐1 receptor agonist ‐based agents and weight loss composition: Filling the gaps
von: Robert L. Dubin, et al.
Veröffentlicht: (2024)

Association of glucagon‐like peptide‐1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes
von: Yu‐Ting Yu, et al.
Veröffentlicht: (2026)

Glucagon‐like peptide‐1 receptor agonists and mental health: A meta‐analysis of randomized controlled trials
von: Giovanni Antonio Silverii, et al.
Veröffentlicht: (2024)

Glucagon‐like peptide‐1 receptor agonists lower risk of cardiovascular and non‐cardiovascular mortality: A meta‐analysis of eleven cardiovascular outcome trials
von: Yu Mi Kang, et al.
Veröffentlicht: (2025)

Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials
von: Claire H. Parker, et al.
Veröffentlicht: (2025)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
von: Hirotaka Watada
Veröffentlicht: (2024)

Glucagon‐like peptide‐1 receptor agonists and incidence of obesity‐related cancer in adults with diabetes: A target‐trial emulation study
von: Lucas A. Mavromatis, et al.
Veröffentlicht: (2025)

Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
von: David C. Klonoff, et al.
Veröffentlicht: (2024)

The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study
von: Zhiyuan Cheng, et al.
Veröffentlicht: (2024)

Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial
von: Carel W. le Roux, et al.
Veröffentlicht: (2024)

Glucagon‐like peptide‐1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta‐analysis
von: Amanda R. Purcell, et al.
Veröffentlicht: (2025)

Glucagon‐like peptide‐1 receptor agonists and the risk of nonarteritic anterior ischaemic optic neuropathy: A systematic review and meta‐analysis of observational studies
von: Ronald M. Goldenberg, et al.
Veröffentlicht: (2025)

Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression
von: Frederick Berro Rivera, et al.
Veröffentlicht: (2024)

Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis
von: Muhammad Aaqib Shamim, et al.
Veröffentlicht: (2024)

Cardiovascular and kidney benefits of GLP ‐1 receptor agonists across large randomized placebo‐controlled trials
von: Satoshi Yoshiji, et al.
Veröffentlicht: (2025)

Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
von: Darren Lau, et al.
Veröffentlicht: (2024)

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
von: Filip K. Knop, et al.
Veröffentlicht: (2024)

Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity
von: Andy Bowe, et al.
Veröffentlicht: (2025)

Unintentional periconceptional exposure to glucagon‐like peptide‐1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan
von: Yi‐Chang Chou, et al.
Veröffentlicht: (2025)

Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes
von: Irl B. Hirsch, et al.
Veröffentlicht: (2024)

Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
von: Yunwen Xu, et al.
Veröffentlicht: (2025)

Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure
von: Karen L. Jones, et al.
Veröffentlicht: (2024)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
von: Iskandar Idris
Veröffentlicht: (2024)

Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium‐glucose cotransporter‐2 inhibitor and glucagon‐like peptide ‐1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease
von: Shunichiro Tsukamoto, et al.
Veröffentlicht: (2024)

Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study
von: Huilin Tang, et al.
Veröffentlicht: (2025)

Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
von: Fu‐Shun Yen, et al.
Veröffentlicht: (2025)

Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes
von: Julio Rosenstock, et al.
Veröffentlicht: (2025)

Glucagon‐like peptide‐1 is involved in fasting and postprandial blood flow regulation of subcutaneous adipose tissue
von: Richard Sotorník, et al.
Veröffentlicht: (2025)

Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis
von: Ruoyang Jiao, et al.
Veröffentlicht: (2024)

Association between glucagon‐like peptide ‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database
von: Tae Hyeon Kim, et al.
Veröffentlicht: (2024)

Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
von: Jason M. Samuels, et al.
Veröffentlicht: (2024)

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials
von: Dongjin Yeo, et al.
Veröffentlicht: (2025)

Efficacy of glucagon‐like peptide‐1 receptor analogues in kidney transplant recipients with diabetes: A single‐centre retrospective study
von: Katie Mei, et al.
Veröffentlicht: (2026)

Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis
von: Conner E. Johnson, et al.
Veröffentlicht: (2024)

Characterisation of real‐world patients who discontinued a glucagon‐like peptide‐1 agonist
von: Jessica Van Laren, et al.
Veröffentlicht: (2026)

Risk of thyroid cancer related to glucagon‐like peptide‐1 receptor agonists: A systematic review with meta‐analysis of harms of randomized controlled trials
von: Lucas Duchemin, et al.
Veröffentlicht: (2025)

Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes
von: Jincheng Shen, et al.
Veröffentlicht: (2025)

Comparative efficacy and safety of Glucagon‐like pepetide‐1 receptor agonists with metformin in Asian versus non‐Asian patients with type 2 diabetes: A systematic review and meta‐analysis
von: Wenxuan Li, et al.
Veröffentlicht: (2025)